Reversing tau pathology to improve serotonin function in early Alzheimer's disease
Reversal of Tau Pathology to Rescue Serotonergic Function in Early Alzheimer’s Disease
This study is looking at whether a special DNA treatment can help fix problems with tau proteins in the brain, which might improve serotonin function and boost brain health for people with early Alzheimer's disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10902655 on NIH RePORTER |
What this research studies
This research investigates how reversing tau protein abnormalities in the brain can help restore serotonin function in patients with early Alzheimer's disease. The approach involves delivering a specific DNA treatment to a brain region affected by tau pathology, aiming to reduce the harmful effects of hyper-phosphorylated tau. By targeting this pathology, the study seeks to understand if it can improve cognitive function and overall brain health in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early Alzheimer's disease who exhibit symptoms related to serotonin dysfunction.
Not a fit: Patients with advanced Alzheimer's disease or those without tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance cognitive function and quality of life for patients with early Alzheimer's disease.
How similar studies have performed: While the approach of targeting tau pathology is gaining interest, this specific method of using PP2A DNA delivery is novel and has not been extensively tested in human subjects.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Kolling, Louis — University of Iowa
- Study coordinator: Kolling, Louis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.